List your tool

Head to head · 2026

Artera vs Belong AI

Pricing, free plans, ratings, features, pros and cons, side by side. Where one comes out ahead, we mark it.

Artera

FDA-cleared multimodal AI that reads biopsy images and clinical data to guide cancer therapy decisions

4.4Not listed

Visit Artera (opens Artera in a new tab)

Belong AI

AI health mentor platform that gives cancer and MS patients conversational support validated by oncologists

4.2Free

Visit Belong AI (opens Belong AI in a new tab)

Who comes out ahead

Based only on the facts in our directory. The right pick still depends on the job you need done.

  • Lower starting price

    Not comparable

    Not comparable: Artera does not list a price

  • Free plan

    Belong AI

    Only Belong AI has one

  • Higher rating

    Artera

    4.4 against 4.2

  • Same job?

    Yes

    Both are Healthcare AI tools

Side by side

Compared onArteraBelong AI
Our rating4.4Better4.2
Starts atNot listedFree
Free planNoYesBetter
CategoryHealthcare AIHealthcare AI
PlansSee pricingFree
Key features
  • Multimodal AI trained on digitized biopsy images paired with clinical data
  • FDA De Novo authorization for the ArteraAI Prostate Test
  • FDA clearance for ArteraAI Breast digital pathology risk stratification
  • Results delivered in as little as two days after sample submission
  • Inclusion in National Comprehensive Cancer Network (NCCN) treatment guidelines
  • Dave: conversational AI cancer mentor validated by oncologists
  • Sophie: AI mentor for multiple sclerosis patients
  • Tara: AI clinical-trial matching by medical profile and location
  • Trained on seven years of patient interaction data
  • Free Dave Community access tier
Pros
  • Regulatory clearance (FDA De Novo, NCCN guideline inclusion) beyond most AI health startups
  • Published clinical evidence showing improved outcome prediction versus existing risk models
  • Adopted by a meaningful share of US prostate cancer clinicians already
  • Medical validation from oncologists affiliated with ASCO and ESMO adds real clinical credibility
  • Free community tier keeps core support accessible regardless of ability to pay
  • Built on a decade of patient community data (Belong.Life founded 2015), not a cold-start chatbot
Cons
  • Not a self-serve software product; access runs through labs, clinicians, and insurance billing
  • Pricing is not public and varies by payer and region
  • Limited to prostate and breast cancer currently, not a general oncology platform
  • Exact DavePro subscription pricing is not published on the company site
  • An AI mentor cannot substitute for a patient's actual oncology care team
  • Sensitive health use case raises a higher bar for data-privacy scrutiny than general chatbots
CompanyArtera, founded 2021Belong.Life, founded 2015

Prices come from each vendor's pricing page, last checked 20260802. Check the vendor before you buy.

FAQ

Questions people ask

Is Artera better than Belong AI?

In our reviews Artera scores 4.4 and Belong AI scores 4.2. The better pick depends on the job. Artera: FDA-cleared multimodal AI that reads biopsy images and clinical data to guide cancer therapy decisions. Belong AI: AI health mentor platform that gives cancer and MS patients conversational support validated by oncologists.

Which is cheaper, Artera or Belong AI?

Artera: see pricing. Belong AI: free.

Do Artera and Belong AI have free plans?

Only Belong AI has a free plan.

More comparisons